Search Results
You are looking at 1 - 3 of 3 items for
- Author: E-J M Speel x
- Refine by access: Content accessible to me x
Search for other papers by Y M H Jonkers in
Google Scholar
PubMed
Search for other papers by S M H Claessen in
Google Scholar
PubMed
Search for other papers by A Perren in
Google Scholar
PubMed
Search for other papers by S Schmid in
Google Scholar
PubMed
Search for other papers by P Komminoth in
Google Scholar
PubMed
Search for other papers by A A Verhofstad in
Google Scholar
PubMed
Search for other papers by L J Hofland in
Google Scholar
PubMed
Search for other papers by R R de Krijger in
Google Scholar
PubMed
Search for other papers by P J Slootweg in
Google Scholar
PubMed
Search for other papers by F C S Ramaekers in
Google Scholar
PubMed
Search for other papers by E-J M Speel in
Google Scholar
PubMed
Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic makeup. Insulinomas represent the predominant syndromic subtype of EPTs. The metastatic potential of insulinomas can frequently not be predicted using histopathological criteria, and also molecular markers indicating malignant progression are unreliable because of the small number of cases per subtype studied so far. For the identification of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and 18 tumors with metastases) by means of comparative genomic hybridization (CGH). In addition, the role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor suppressor gene. Only one case with a somatic MEN1 mutation was identified (1527del7bp), indicating that the MEN1 gene plays a minor pathogenic role in sporadic insulinomas. CGH analysis revealed that the total number of aberrations per tumor differs strongly between the benign and the malignant group (4.2 vs 14.1; P<0.0001). Furthermore, chromosome 9q gain was found to be the most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease. Our study shows that chromosomal instability, as defined by ≥5 gains together with ≥5 losses, or total number of gains and losses ≥8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.
Search for other papers by Mieke E R Henfling in
Google Scholar
PubMed
Search for other papers by Aurel A Perren in
Google Scholar
PubMed
Search for other papers by Anja M Schmitt in
Google Scholar
PubMed
Search for other papers by Christiane M Saddig in
Google Scholar
PubMed
Search for other papers by Achim A Starke in
Google Scholar
PubMed
Search for other papers by Robert G Riedl in
Google Scholar
PubMed
Search for other papers by Yvonne M H Versleijen-Jonkers in
Google Scholar
PubMed
Search for other papers by Diana M Sprij-Mooij in
Google Scholar
PubMed
Search for other papers by Frans C S Ramaekers in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by Ernst-Jan M Speel in
Google Scholar
PubMed
Clinical and molecular studies have implicated epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF) and target of rapamycin (mTOR) signaling pathways in the regulation of pancreatic neuroendocrine tumor (PanNET) growth. Interpretation and comparison of these studies is complex due to clinical and molecular tumor heterogeneity. We therefore focused in this study on insulinomas, which we examined for mRNA and protein expression of EGFR, IGF and mTOR signaling pathway components by quantitative real-time PCR (n = 48) and immunohistochemistry (n = 86). Findings were compared with normal pancreatic islets and correlated with histopathological data and clinical outcome. Insulinomas showed low EGFR and high IGF2 expression. IGFBP2, IGFBP3 and IGFBP6 mRNA levels were 2- to 4-folds higher than those in islets. High protein expression of IGF2, IGF1R and INSR (in 51–92% of the tumors) and low-to-moderate expression of mTORC1 pathway proteins p-S6k and p-4EBP1 (7–28% of the tumors) were observed. Correlations were found between (1) ERK1 mRNA expression and that of numerous IGF pathway genes, (2) p-ERK and IGF1R protein expression and (3) decrease of IGF pathway components and both metastatic disease and shorter 10-year disease-free survival. In conclusion, our observations suggest that high expression of IGF signaling pathway components is a hallmark of insulinomas, but does not necessarily lead to increased mTOR signaling. Reduced expression of IGF pathway components may be an adverse prognostic factor in insulinomas.
Search for other papers by Y M H Jonkers in
Google Scholar
PubMed
Search for other papers by S M H Claessen in
Google Scholar
PubMed
Search for other papers by A Perren in
Google Scholar
PubMed
Search for other papers by A M Schmitt in
Google Scholar
PubMed
Search for other papers by L J Hofland in
Google Scholar
PubMed
Search for other papers by W de Herder in
Google Scholar
PubMed
Search for other papers by R R de Krijger in
Google Scholar
PubMed
Search for other papers by A A J Verhofstad in
Google Scholar
PubMed
Search for other papers by A R Hermus in
Google Scholar
PubMed
Search for other papers by J A Kummer in
Google Scholar
PubMed
Search for other papers by B Skogseid in
Google Scholar
PubMed
Search for other papers by M Volante in
Google Scholar
PubMed
Search for other papers by A C Voogd in
Google Scholar
PubMed
Search for other papers by F C S Ramaekers in
Google Scholar
PubMed
Search for other papers by E J M Speel in
Google Scholar
PubMed
The clinical behavior of endocrine pancreatic tumors (EPTs) is difficult to predict in the absence of metastases or invasion to adjacent organs. Several markers have been indicated as potential predictors of metastatic disease, such as tumor size ≥2 cm, Ki67 proliferative index ≥2%, cytokeratin (CK) 19 status, and recently in insulinomas, chromosomal instability (CIN). The goal of this study was to evaluate the value of these markers, and in particular of the CIN, to predict tumor recurrence or progression and tumor-specific death, using a series of 47 insulinomas and 24 non-insulinoma EPTs. From these EPT cases, a genomic profile has been generated and follow-up data have been obtained. The proliferative index has been determined in 68 tumors and a CK19 expression pattern in 50 tumors. Results are statistically analyzed using Kaplan–Meier plots and the log-rank statistic. General CIN, as well as specific chromosomal alterations such as 3p and 6q loss and 12q gain, turned out to be the most powerful indicators for poor tumor-free survival (P≤0.0004) and tumor-specific death (P≤0.0113) in insulinomas. The CIN, chromosome 7q gain, and a proliferative index ≥2% were reliable in predicting a poor tumor-free survival in non-insulinoma EPTs (P≤0.0181, whereas CK19 expression was the most optimal predictor of tumor-specific death in these tumors. In conclusion, DNA copy number status is the most sensitive and efficient marker of adverse clinical outcome in insulinomas and of potential interest in non-insulinoma EPTs. As a consequence, this marker should be considered as a prognosticator to improve clinical diagnosis, most practically as a simple multi-target test.